MURATORE, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.820
AS - Asia 6.054
EU - Europa 4.218
SA - Sud America 928
AF - Africa 104
OC - Oceania 33
Continente sconosciuto - Info sul continente non disponibili 5
Totale 22.162
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.628
SG - Singapore 2.083
CN - Cina 1.593
GB - Regno Unito 940
IT - Italia 937
BR - Brasile 713
HK - Hong Kong 710
VN - Vietnam 634
FI - Finlandia 489
SE - Svezia 389
DE - Germania 386
RU - Federazione Russa 241
FR - Francia 213
BD - Bangladesh 200
KR - Corea 193
UA - Ucraina 147
TR - Turchia 135
NL - Olanda 96
BG - Bulgaria 89
AR - Argentina 85
ID - Indonesia 83
IN - India 83
CA - Canada 76
JP - Giappone 67
AT - Austria 55
MX - Messico 55
IQ - Iraq 53
AE - Emirati Arabi Uniti 35
ES - Italia 33
PL - Polonia 32
AU - Australia 30
EC - Ecuador 30
ZA - Sudafrica 30
IE - Irlanda 29
PK - Pakistan 29
CL - Cile 25
LT - Lituania 23
MA - Marocco 23
VE - Venezuela 21
BZ - Belize 20
CO - Colombia 19
BE - Belgio 18
UZ - Uzbekistan 17
PH - Filippine 16
CH - Svizzera 14
KW - Kuwait 14
PT - Portogallo 14
CZ - Repubblica Ceca 13
PE - Perù 13
HU - Ungheria 12
MY - Malesia 12
NP - Nepal 12
SA - Arabia Saudita 11
DZ - Algeria 10
DO - Repubblica Dominicana 9
KE - Kenya 9
TH - Thailandia 9
TW - Taiwan 9
AZ - Azerbaigian 8
KG - Kirghizistan 8
PY - Paraguay 8
EG - Egitto 7
UY - Uruguay 7
AL - Albania 6
IL - Israele 6
JO - Giordania 6
RO - Romania 6
TN - Tunisia 6
EE - Estonia 5
EU - Europa 5
GR - Grecia 5
GT - Guatemala 5
LV - Lettonia 5
PR - Porto Rico 5
IR - Iran 4
JM - Giamaica 4
SN - Senegal 4
BO - Bolivia 3
BY - Bielorussia 3
CR - Costa Rica 3
DK - Danimarca 3
GY - Guiana 3
KH - Cambogia 3
LB - Libano 3
MT - Malta 3
NZ - Nuova Zelanda 3
OM - Oman 3
SV - El Salvador 3
AM - Armenia 2
AO - Angola 2
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
CI - Costa d'Avorio 2
CU - Cuba 2
ET - Etiopia 2
KY - Cayman, isole 2
KZ - Kazakistan 2
NI - Nicaragua 2
PS - Palestinian Territory 2
QA - Qatar 2
Totale 22.131
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.498
Singapore 1.256
Ashburn 1.096
Fairfield 1.026
Hong Kong 701
Woodbridge 574
Hefei 571
San Jose 554
Houston 471
Southend 461
Seattle 442
Chandler 438
Helsinki 433
Wilmington 323
Cambridge 305
London 291
Beijing 265
Ann Arbor 255
Nyköping 235
Ho Chi Minh City 225
New York 215
Jacksonville 211
Council Bluffs 204
The Dalles 204
Dearborn 193
Seoul 189
Modena 180
Los Angeles 159
Munich 146
Hanoi 135
Dallas 111
Lauterbourg 110
Milan 107
Chicago 105
San Diego 101
Moscow 98
Buffalo 81
Princeton 78
Sofia 78
São Paulo 69
Shanghai 63
Jakarta 54
Eugene 51
Boardman 45
Bologna 42
Salt Lake City 41
Tokyo 40
Nuremberg 39
Izmir 37
Redondo Beach 37
Amsterdam 36
Columbus 35
Rio de Janeiro 35
Orem 34
Kent 33
Frankfurt am Main 30
Haiphong 30
Redwood City 29
Rome 28
Dublin 27
Toronto 26
Atlanta 24
Brooklyn 24
Da Nang 24
Elk Grove Village 24
Florence 22
Guangzhou 21
Mexico City 21
Reggio Emilia 21
Belize City 20
Vienna 20
Johannesburg 19
Lappeenranta 19
Brasília 18
Montreal 18
Brussels 17
Chennai 17
Phoenix 17
Denver 16
Miano 16
Ankara 15
Baghdad 15
Kilburn 15
Las Vegas 15
Portsmouth 15
Tashkent 15
Warsaw 15
Kuwait City 14
Palermo 14
Quito 14
Delft 13
Falls Church 13
Mumbai 13
Naples 13
Paris 13
Porto Alegre 13
Tampa 13
Norwalk 12
Parma 12
Istanbul 11
Totale 15.637
Salva come PNG Salva come JPEG
Nome #
Visual loss and other cranial ischaemic complications in giant cell arteritis 334
Rituximab therapy for Takayasu arteritis: A seven patients experience and a review of the literature 331
VEXAS Syndrome: A Case Series From a Single-Center Cohort of Italian Patients With Vasculitis 331
A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility 308
Ultrasound Examination of Common Carotid Adventitial Thickness Can Differentiate Takayasu Arteritis and Large Vessel Giant Cell Arteritis 298
Inflamed temporal artery: histologic findings in 354 biopsies, with clinical correlations 289
Decreased bone cortical density at the forearm in subjects with subclinical peripheral arterial disease 287
Aortic dilatation in patients with large vessel vasculitis: A longitudinal case control study using PET/CT 285
L-arginine supplementation normalizes bone turnover and preserves bone mass in streptozotocin-induced diabetic rats 284
Correlations between histopathological findings and clinical manifestations in biopsy-proven giant cell arteritis 280
Comparison between colour duplex sonography findings and different histological patterns of temporal artery 278
Biotherapies in large vessel vasculitis 276
Imaging of vasculitis: State of the art 275
Comment on: Rituximab therapy for takayasu arteritis: A seven patients experience and a review of the literature: Reply 274
Contribution of the new 2012 EULAR/ACR classification criteria for the diagnosis of polymyalgia rheumatica 271
Unmet Needs in the Pathogenesis and Treatment of Vasculitides 269
Recent advances in the diagnosis and treatment of polymyalgia rheumatica 265
Biologics in vasculitides: Where do we stand, where do we go from now? 260
MicroRNA markers of inflammation and remodelling in temporal arteries from patients with giant cell arteritis 256
Increased expression of interleukin-22 in patients with giant cell arteritis 253
Is colour duplex sonography-guided temporal artery biopsy useful in the diagnosis of giant cell arteritis? A randomized study 252
Higher Frequencies of Lymphocytes Expressing the Natural Killer Group 2D Receptor in Patients With Behçet Disease 252
Long-term remission in biopsy proven giant cell arteritis: A retrospective cohort study 250
Histopathologic Findings of Patients With Biopsy-Negative Giant Cell Arteritis Compared to Those Without Arteritis: A Population-Based Study 245
Acute-phase reactants during tocilizumab therapy for severe COVID-19 pneumonia 245
Incidence, prevalence and survival of biopsy-proven giant cell arteritis in Northern Italy during a 26-year period 239
No detection of varicella-zoster virus in temporal arteries of patients with giant cell arteritis 239
Aortic dilatation in a patient with Takayasu arteritis treated with tocilizumab 233
Thoracic Hyper-IgG4-Related Disease Mimicking Malignant Pleural Mesothelioma 231
Association Between Specimen Length and Number of Sections and Diagnostic Yield of Temporal Artery Biopsy for Giant Cell Arteritis 230
Cardiac and Pulmonary Artery Involvement Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Large-vessel Giant Cell Arteritis 227
Reduction of volumetric bone mineral density in postmenopausal women with hepatitis C virus-correlated chronic liver disease: a peripheral quantitative computed tomography (pQCT) study 226
Updates on the diagnosis and monitoring of giant cell arteritis 223
Small-vessel vasculitis surrounding an uninflamed temporal artery and isolated vasa vasorum vasculitis of the temporal artery: two subsets of giant cell arteritis 221
Statin use in giant cell arteritis: a retrospective study 220
Effectiveness of Infliximab and Interferon Alpha-2a for the Treatment of Behçet’s Uveitis: Customizing Therapy according to the Clinical Features 216
Large-vessel giant cell arteritis: a cohort study 215
Tocilizumab for the treatment of giant cell arteritis 214
Mycophenolate mofetil in primary central nervous system vasculitis 214
Large-Vessel Dilatation in Giant Cell Arteritis: A Different Subset of Disease? 213
Is PET/CT essential in the diagnosis and follow-up of temporal arteritis? 212
Extra-cranial giant cell arteritis and Takayasu arteritis: How similar are they? 212
Survival predictors in biopsy-proven giant cell arteritis: A northern Italian population-based study 208
Rituximab therapy for primary central nervous system vasculitis: A 6 patient experience and review of the literature 207
Standard and biological treatment in large vessel vasculitis: guidelines and current approaches 202
Age at diagnosis influences the clinical phenotype, treatment strategies and outcomes in patients with giant cell arteritis: results from the observational GCAGE study on a large cohort of 1004 patients 198
Chronic periaortitis presenting with isolated pulmonary artery involvement: description of two cases 198
Effectiveness and safety of a 26-week taper regimen of glucocorticoid in GCA patients: Results from a prospective cohort study 196
Interleukin-6 and soluble interleukin-6 receptor are elevated in large-vessel vasculitis: a cross-sectional and longitudinal study 195
Human Dental Pulp Stem Cells Modulate Cytokine Production in vitro by Peripheral Blood Mononuclear Cells From Coronavirus Disease 2019 Patients 194
Flares in Biopsy-Proven Giant Cell Arteritis in Northern Italy: Characteristics and Predictors in a Long-Term Follow-Up Study 189
Incidence and prevalence of large vessel vasculitis (giant cell arteritis and Takayasu arteritis) in northern Italy: A population-based study 189
miR-146a and miR-146b regulate the expression of ICAM-1 in giant cell arteritis 187
L30. Assessment of vasculitis extent and severity 187
Elevated NET, Calprotectin, and Neopterin Levels Discriminate between Disease Activity in COVID-19, as Evidenced by Need for Hospitalization among Patients in Northern Italy 186
The therapeutic potential of tuftsin-phosphorylcholine in giant cell arteritis 182
Efficacy of Methotrexate in Real-world Management of Giant Cell Arteritis: A Case-control Study 181
Clinical Features and Prevalence of Spondyloarthritis in a Cohort of Italian Patients Presenting with Acute Nongranulomatous Anterior Uveitis 179
Reggio Emilia (Northern Italy) Interdisciplinary Uveitis Clinic: What We Have Learned in the Last 20 Years 178
Susceptibility to COVID-19 in Patients Treated With Antimalarials: A Population-Based Study in Emilia-Romagna, Northern Italy 177
Efficacy and safety of TNF-α antagonists and tocilizumab in Takayasu arteritis: Multicenter retrospective study of 209 patients 177
Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes 173
Giant Cell Arteritis and Polymyalgia Rheumatica 172
Resolution of vascular inflammation in patients with new-onset giant cell arteritis: data from the RIGA study 170
Extra-articular rheumatoid arthritis imaged by [18F]FDG-PET/CT 169
Vessel inflammation and morphological changes in patients with large vessel vasculitis: A retrospective study 168
Significance of inflammation restricted to adventitial/periadventitial tissue on temporal artery biopsy 167
Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: results from the extension of the TOPAZIO study 166
Discontinuation of therapies in polymyalgia rheumatica and giant cell arteritis 163
Relapses and long-term remission in large vessel giant cell arteritis in northern Italy: Characteristics and predictors in a long-term follow-up study 162
Identification of two autoantigens recognised by circulating autoantibodies as potential biomarkers for diagnosing giant cell arteritis 160
Large-vessel involvement in giant cell arteritis and polymyalgia rheumatica 160
Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: A population-based study 160
Distribution patterns of 18F-fluorodeoxyglucose in large vessels of Takayasu's and giant cell arteritis using positron emission tomography 158
Prevalence and distribution of vascular calcifications at CT scan in patients with and without large vessel vasculitis: A matched cross-sectional study 155
Effects in soluble immune checkpoints induced by Tocilizumab monotherapy after ultra-short-term glucocorticoids in large vessel – giant cell arteritis patients 153
The role of sacro-iliac joint magnetic resonance imaging in the diagnosis of axial spondyloarthritis: focus on differential diagnosis in women 150
Development of the Takayasu Arteritis Integrated Disease Activity Index 149
Senescent cells in giant cell arteritis display an inflammatory phenotype participating in tissue injury via IL-6-dependent pathways 148
Steroid-sparing agents in polymyalgia rheumatica: how will they fit into the treatment paradigm? 147
The Italian Society of Rheumatology clinical practice guidelines for the management of large vessel vasculitis 147
Isolated vasculitis of the lower extremities in a patient with polymyalgia rheumatica and giant cell arteritis 146
Tofacitinib for the treatment of refractory Takayasu's arteritis: description of 2 cases 146
Failure of first anti-TNF agent in Takayasu's arteritis: to switch or to swap? 144
What to Know About Biopsy Sampling and Pathology in Vasculitis? 142
Corrigendum to: Increased expression of interleukin-22 in patients with giant cell arteritis 142
Vogt–Koyanagi–Harada patients show higher frequencies of circulating NKG2Dpos NK and NK T cells 142
Cytokine Profiling in Aqueous Humor Samples From Patients With Non-Infectious Uveitis Associated With Systemic Inflammatory Diseases 140
Eosinophilic giant cell arteritis: A different subset of disease? 138
Role of miR-146a and miR-146b in Giant Cell Arteritis. 136
Comparison of biopsy-proven giant cell arteritis in North America and Southern Europe: a population-based study 136
Interstitial lung disease in microscopic polyangiitis and granulomatosis with polyangiitis: demographic, clinical, serological and radiological features of an Italian cohort from the Italian Society for Rheumatology 135
Insight into giant cell arteritis pathogenesis by NanoString nCounter gene expression profiling in temporal artery biopsies 134
C-reactive protein gene polymorphisms influence susceptibility and outcomes of biopsy-proven giant cell arteritis in Italian patients 132
Genes deregulated in giant cell arteritis by Nanostring nCounter gene expression profiling in temporal artery biopsies 131
Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study 130
State of the art of 18F-FDG PET/CT application in inflammation and infection: a guide for image acquisition and interpretation 130
The role of PET/CT in disease activity assessment in patients with large vessel vasculitis 129
Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: the role of imaging in a prospective observational study 128
IgG4-associated sclerosing mesenteritis 127
Totale 20.128
Salva come PNG Salva come JPEG
Categoria #
all - tutte 90.891
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 90.891
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021118 0 0 0 0 0 0 0 0 0 0 0 118
2021/20221.390 77 95 104 83 45 116 131 52 150 114 262 161
2022/20231.409 166 151 111 113 147 183 44 108 206 25 76 79
2023/20241.082 19 70 50 100 190 134 98 172 28 27 63 131
2024/20254.963 138 47 75 340 1.050 819 402 222 528 320 503 519
2025/20268.450 640 409 765 867 949 609 1.190 450 952 677 793 149
Totale 22.381